Navigation Links
CTI Announces Data Presentations at the 18th Congress of the European Hematology Association
Date:6/10/2013

studies of pacritinib, a non-myelosuppressive JAK2/FLT3 inhibitor, in patients with hematological malignancies
Presentation Date/Time/Location: Friday, June 14, 5:45 to 7:00 p.m. CEST, Poster Hall
First Author: Dr. S. Verstovsek, MD Anderson Cancer Center, Houston, United States

Abstract Number: P983
Poster Title: Characterization of the pharmacokinetic and pharmacodynamic properties of pacritinib, a novel oral JAK2/FLT3 inhibitor, in patients with myelofibrosis, AML and lymphoma
Presentation Date/Time/Location: Poster session, Saturday, June 15, 5:45 to 7:00 p.m. CEST, Poster Hall
First Author: Dr. Suliman Al-Fayoumi, Cell Therapeutics, Seattle, United States

About PIXUVRI (pixantrone)

PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Unlike related compounds, PIXUVRI forms stable DNA adducts and in preclinical models has superior anti-lymphoma activity compared to related compounds. PIXUVRI was structurally designed so that it cannot bind iron and perpetuate oxygen radical production or form a long-lived hydroxyl metabolite -- both of which are the putative mechanisms for anthracycline induced acute and chronic cardiotoxicity. These novel pharmacologic properties allow PIXUVRI to be administered to patients with near maximal lifetime exposure to anthracyclines without unacceptable rates of cardiotoxicity.

In May 2012, the European Commission granted conditional marketing authorization for PIXUVRI as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive NHL based on the results of the EXTEND, or PIX301, pivotal randomized Phase 3 clinical trial. The benefit of PIXUVRI treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are ref
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 Telik, Inc. (OTCQB: TELK), ... merged with MabVax Therapeutics, Inc. on July 8, ... related to the development of its lead antibody ... using the Company,s internally developed antibody discovery platform. ... multiple antibody based therapeutic and diagnostic products based ...
(Date:8/28/2014)... N.H. , Aug. 28, 2014  Critical ... Hampshire , today announces the expansion of ... Critical Process Filtration now offers customers and ... in fluids to filter failure analyses (even for ... addition to their hallmark services of system benchmarking ...
(Date:8/28/2014)... , Aug. 28, 2014  A decline in ... generics are adding pressure to pharmaceutical, biotechnology and ... resources continue to shrink and approval processes and ... led companies to look for additional support and ... for keeping approved products on the market.  ...
Breaking Medicine Technology:Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4Critical Process Filtration, Inc. Announces Expanded Technical Services and Validation Support 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4
... People recovering,from acute heart problems such as ... develop habits to control heart attack risk factors ... to researchers at,Mayo Clinic in Rochester. These managers ... programs that last,three years. With these risk factors ...
... 4 AstraZeneca (NYSE:,AZN) today announced that it ... U.S. Food and Drug Administration (FDA) for approval ... Aerosol for the long-term maintenance treatment of asthma ... SYMBICORT is currently approved,for the long-term maintenance treatment ...
Cached Medicine Technology:Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows 2Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows 3Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows 4AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 2AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 3AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 4AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 5AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 6
(Date:8/28/2014)... plans its exit strategy from the war, now may be ... health care to veterans, says a Perspective piece in the ... go on doing more of the same is to fail ... and population structure pose in the longer run," said William ... Practice, and David Auerbach, from the RAND Corporation, in the ...
(Date:8/28/2014)... The Governor of Yucatán, Rolando Zapata Bello, ... press conference; this event is organized by the Microcredit ... through the National Microenterprise Financing Program ( PRONAFIM ) ... 5th at the Convention Center Yucatan Siglo XXI in ... responsibility for Yucatan to host the 17th Microcredit Summit ...
(Date:8/28/2014)... Bank lending to the private sector in the ... in real terms, and continuing to fall behind the rest ... the international accountancy network. , UHY warns that the figures ... credit crunch lingers on. , UHY says in the US, ... been wiped out by inflation. Over the four years since ...
(Date:8/28/2014)... did the earliest birds take wing? Did they fall from ... Or did they run along the ground and pump their ... million years in the past, but a new University of ... birds have an innate ability to maneuver in midair, a ... rather than fall from a perch. , The study looked ...
(Date:8/28/2014)... August 28, 2014 (BRONX, NY) Researchers from ... other institutions have developed a potential antibody therapy for Sudan ... Ebola. A different strain, the Zaire ebolavirus (EBOV), is now ... numerous Ebola outbreaks (most recently in 2012) that ... were reported in ACS Chemical Biology . , ...
Breaking Medicine News(10 mins):Health News:A VA exit strategy 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:Drug shows promise against Sudan strain of Ebola in mice 2
... carcinoma in situDCISwho later develop invasive breast cancer in ... from breast cancer than those who do not develop ... 11 in the Journal of the National Cancer ... have compared breast conserving surgery (lumpectomy) to mastectomy and ...
... , FRIDAY, March 11 (HealthDay News) -- Taking ... but mostly in people at increased risk for the ... in their blood, according to a new study. ... or other nonsteroidal anti-inflammatory drugs (NSAIDs) have a reduced ...
... March 11 (HealthDay News) -- Watching your team win a ... be thrilling, but there may be a drawback: aggressive, testosterone-fueled ... found that traffic deaths at the game site and the ... game is over. Researchers at North Carolina State University ...
... are a burning issue. A straightforward guide to a closer understanding ... 2011). The Dose Makes the Poison: A Plain-Language Guide to Toxicology, ... leads to a distortion in many people,s conceptions of toxins and ... We are exposed to media reports on a daily basis of ...
... DETROIT Theories have long proposed that testosterone influences ... a recent study at Wayne State University give a ... mating behavior, and how testosterone is associated with dominance ... of an attractive woman. The study engaged ...
... causes AIDS invades human immune cells and causes ... can then infect new cells. A research team led ... Priv.-Doz. Dr. Barbara Mller of Heidelberg University Hospital have ... infected cell in virion release, and discovered that the ...
Cached Medicine News:Health News:DCIS patients who get invasive breast cancer have higher mortality 2Health News:Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People 2Health News:Fans of Winning Teams Linked to Fatal Crashes 2Health News:'The Dose Makes the Poison: A Plain-Language Guide to Toxicology,' 3rd Edition 2Health News:Wayne State study links testosterone with men's ability to 'woo' potential mates 2Health News:Pushing HIV out the door: How host factors aid in the release of HIV particles 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: